Capped nascent RNA sequencing reveals novel therapy-responsive enhancers in prostate cancer
暂无分享,去创建一个
M. Gerstein | M. Rubin | Haiyuan Yu | S. Lou | K. Cotter | Sagar R. Shah | Mauricio I. Paramo | Li Yao | Philip D. Rubin | You Chen
[1] Haiyuan Yu,et al. A comparison of experimental assays and analytical methods for genome-wide identification of active enhancers , 2022, Nature Biotechnology.
[2] K. D. Sørensen,et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction , 2021, Nature genetics.
[3] Sylvan C. Baca,et al. H3k27ac-HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility , 2020 .
[4] Han Liang,et al. A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer. , 2020, Cancer cell.
[5] H. G. van der Poel,et al. Functional mapping of androgen receptor enhancer activity , 2020, Genome Biology.
[6] Fidencio J. Neri,et al. Index and biological spectrum of human DNase I hypersensitive sites , 2020, Nature.
[7] Henry W. Long,et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression , 2020, Nature Genetics.
[8] Michael Q. Zhang,et al. The landscape of RNA polymerase II associated chromatin interactions in prostate cancer. , 2020, The Journal of clinical investigation.
[9] Castration Resistance , 2020, Definitions.
[10] J. Shendure,et al. Towards a comprehensive catalogue of validated and target-linked human enhancers , 2020, Nature Reviews Genetics.
[11] Runan Yao,et al. ShinyGO: a graphical gene-set enrichment tool for animals and plants , 2019, Bioinform..
[12] B. Győrffy,et al. TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth , 2019, eLife.
[13] Henry W. Long,et al. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer , 2019, Cell reports.
[14] Shayne D. Wierbowski,et al. Transcription imparts architecture, function, and logic to enhancer units , 2019, Nature Genetics.
[15] P. Farnham,et al. A high-resolution 3D epigenomic map reveals insights into the creation of the prostate cancer transcriptome , 2019, Nature Communications.
[16] I. Asangani,et al. CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation. , 2019, Cancer discovery.
[17] Nicola J. Rinaldi,et al. An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells , 2019, Genome research.
[18] Prashant S. Emani,et al. Comprehensive functional genomic resource and integrative model for the human brain , 2018, Science.
[19] Kendall R. Sanson,et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities , 2018, Nature Communications.
[20] J. Licht,et al. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator , 2018, Cell reports.
[21] L. Wessels,et al. Integrative epigenetic taxonomy of primary prostate cancer , 2018, Nature Communications.
[22] Joshua M. Stuart,et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.
[23] Christopher W. Whelan,et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing , 2018, Cell.
[24] Henry W. Long,et al. A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer , 2018, Cell.
[25] J. Weinstein,et al. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. , 2018, Cell.
[26] Yi Mi Wu,et al. The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.
[27] J. Lis,et al. Enhancer transcription: what, where, when, and why? , 2018, Genes & development.
[28] M. Rubin,et al. Differential impact of RB status on E2F1 reprogramming in human cancer , 2017, The Journal of clinical investigation.
[29] Brent S. Pedersen,et al. GIGGLE: a search engine for large-scale integrated genome analysis , 2017, Nature Methods.
[30] Christopher A. Lavender,et al. Widespread transcriptional pausing and elongation control at enhancers , 2018, Genes & development.
[31] M. Rubin,et al. Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. , 2017, Cancer cell.
[32] A. Gursoy,et al. Androgen receptor binding sites are highly mutated in prostate cancer , 2017, bioRxiv.
[33] K. White,et al. Functional assessment of human enhancer activities using whole-genome STARR-sequencing , 2017, Genome Biology.
[34] Takafumi N. Yamaguchi,et al. TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer , 2017, Nature Genetics.
[35] J. Carroll,et al. Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. , 2017, Cancer research.
[36] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[37] Alain Bergeron,et al. Genomic hallmarks of localized, non-indolent prostate cancer , 2017, Nature.
[38] Tao Liu,et al. Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse , 2016, Nucleic Acids Res..
[39] Leighton J. Core,et al. Base-pair-resolution genome-wide mapping of active RNA polymerases using precision nuclear run-on (PRO-seq) , 2016, Nature Protocols.
[40] S. Fox,et al. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. , 2016, European journal of cancer.
[41] Fidel Ramírez,et al. deepTools2: a next generation web server for deep-sequencing data analysis , 2016, Nucleic Acids Res..
[42] Aaron T. L. Lun,et al. Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations , 2016, Genome research.
[43] Meagan E. Sullender,et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.
[44] Henry W. Long,et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.
[45] Lan T M Dao,et al. High-throughput and quantitative assessment of enhancer activity in mammals by CapStarr-seq , 2015, Nature Communications.
[46] S. Dhanasekaran,et al. Targeting the MLL complex in castration resistant prostate cancer , 2015, Nature Medicine.
[47] André L. Martins,et al. Analysis of nascent RNA identifies a unified architecture of initiation regions at mammalian promoters and enhancers , 2014, Nature Genetics.
[48] Kevin Y. Yip,et al. FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer , 2014, Genome Biology.
[49] B. Cohen,et al. High-throughput functional testing of ENCODE segmentation predictions , 2014, Genome research.
[50] T. Mikkelsen,et al. Systematic dissection of regulatory motifs in 2000 predicted human enhancers using a massively parallel reporter assay. , 2013, Genome research.
[51] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[52] Łukasz M. Boryń,et al. Genome-Wide Quantitative Enhancer Activity Maps Identified by STARR-seq , 2013, Science.
[53] I. Mills,et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. , 2013, Cancer cell.
[54] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[55] Wing-Kin Sung,et al. Integration of Regulatory Networks by NKX3-1 Promotes Androgen-Dependent Prostate Cancer Survival , 2012, Molecular and Cellular Biology.
[56] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[57] G. Kreiman,et al. Widespread transcription at neuronal activity-regulated enhancers , 2010, Nature.
[58] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[59] Arul M Chinnaiyan,et al. Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States , 2009, Clinical Cancer Research.
[60] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[61] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] J. Trapman,et al. The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.
[63] G. Bubley,et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.
[64] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.
[65] G. Murphy,et al. LNCaP model of human prostatic carcinoma. , 1983, Cancer research.